ATTR phenotypes vary by genotype as well as by gene penetrance, age, and geographic location. A new analysis examined data from untreated, symptomatic patients who had 1 of 4 variants: F64L, I68L, ...
Acoramidis significantly reduced all-cause mortality in both wild-type and variant amyloid cardiomyopathy through 42 months of the ATTRibute-CM study. The study demonstrated consistent efficacy in ...
Everyday Health on MSN
Genetic testing and ATTR-CM: Everything you need to know
Learn why genetic testing is vital for ATTR-CM diagnosis, how it identifies hereditary risks for family members, and the ...
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending vutrisiran for patients with wild-type and hereditary transthyretin amyloidosis with ...
Meet Raymond and Alan, two people diagnosed with transthyretin cardiac amyloidosis (ATTR-CM), a rare and underdiagnosed cause of heart failure. 1 Both led active, healthy lives before experiencing ...
Delayed diagnosis of wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) results in inappropriate treatments prior to diagnosis and worse clinical outcomes after diagnosis. Transthyretin amyloid ...
Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results